MEDICAL WEIGHT MANAGEMENT · SINGAPORE

Oral Semaglutide: The Daily GLP-1 Tablet

The semaglutide tablet is registered in Singapore for type 2 diabetes. Here is how it works, why the morning routine matters, what the trials show for weight and blood sugar, and how it compares with the weekly injection.

Struggling with weight loss for years?
Get a doctor-prescribed solution to regulate appetite and supports sustainable weight loss by addressing hormonal and metabolic factors.

30 min

Wait before food or drink (3)

120 ml

Most water to take it with (3)

14 mg

Highest daily diabetes dose (3)

💡

A note on terminology

This page uses semaglutide, the generic name, for both the daily tablet and the weekly injection, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where the semaglutide tablet stands today

The tablet and the injection share an active ingredient but not a registered use. It is worth being clear on the difference before you see a doctor.

✓ 2019 — First GLP-1 tablet approved. US regulators approved oral semaglutide for adults with type 2 diabetes, the first GLP-1 medicine available as a tablet. (1)

✓ Singapore — Registered for type 2 diabetes. Here, the tablet is registered to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. (5)

✓ Late 2025 — Higher-strength tablet approved overseas for weight. US regulators approved a 25 mg daily semaglutide tablet for chronic weight management, based on the OASIS trials. It is a different product from the diabetes tablet. (4)

▸ Weight management — Not registered in Singapore. The diabetes tablet is not registered here for weight loss. Using it for weight alone would be off-label, and is a decision for a doctor after a full assessment. (5)

Why the tablet needs a strict routine

Semaglutide is a peptide, a small protein that stomach acid normally breaks down. Swallowed on its own, almost none of it would reach the bloodstream.

The tablet contains an absorption enhancer called SNAC, which briefly protects semaglutide and helps it cross the stomach lining. That protection only lasts a short time, and food, drinks or other tablets easily disrupt it. (2)

That is why the timing rules matter. Even when they are followed, only a small fraction of each tablet is absorbed, so tablet doses are measured in milligrams per day rather than fractions of a milligram per week.

Fig. 1 — The morning routine for the semaglutide tablet: empty stomach, up to 120 ml of water, wait 30 minutes.
Fig. 1 — The morning routine for the semaglutide tablet.
Fig. 2 — Semaglutide tablet doses stepped up from 3 mg to 7 mg to 14 mg a day.
Fig. 2 — Daily doses are stepped up over at least two months.

What the trials show on weight

Oral semaglutide has been studied at two very different strengths: the diabetes doses (up to 14 mg a day) in the PIONEER trials, and much higher doses made for weight management in the OASIS trials. (3) (4)

Trial

Population (n)

Dose and duration

Weight change

Placebo

PIONEER 1

703 · type 2 diabetes

14 mg a day, 26 weeks

-3.7 kg

-1.4 kg

OASIS 4

307 · obesity or overweight

25 mg a day, 64 weeks

-13.6%

-2.2%

PIONEER: the diabetes doses

In people with type 2 diabetes, the 14 mg tablet lowered HbA1c and led to modest weight loss, about 3 to 4 kg on average over six months. That is useful, but much less than with medicines designed for weight management. (3)

OASIS: higher doses for weight

When much higher daily doses were tested in people with obesity, weight loss was far larger: 13.6% with 25 mg over 64 weeks in OASIS 4, and 15.1% with 50 mg over 68 weeks in OASIS 1, compared with about 2% on placebo. (4) (6)

Fig. 3 — Average weight change with high-dose oral semaglutide versus placebo in OASIS 1 and OASIS 4.
Fig. 3 — Average change in body weight with high-dose oral semaglutide versus placebo. Source: OASIS 1 and OASIS 4 (4)(6).
What else changes on treatment?

Alongside weight, oral semaglutide was associated with improvements in:

  • HbA1c (average blood sugar)
  • Fasting blood glucose
  • Waist circumference
  • Body mass index (BMI)
  • Systolic blood pressure
  • Triglycerides

In people with type 2 diabetes and heart or kidney disease, a large outcome trial (SOUL) found that oral semaglutide reduced major cardiovascular events compared with placebo. (7)

Results depend heavily on taking the tablet correctly every morning. Missed or mistimed doses are one of the most common reasons the tablet seems not to work.

Who may be suitable?

Your doctor will look at your diagnosis, your BMI using Asian cut-offs, blood sugar, kidney function, other medicines, and whether a daily morning routine is realistic for you. People with a personal or family history of medullary thyroid cancer or MEN2 should not take semaglutide. (5) (8)

Tablet or weekly injection?

Both contain semaglutide, but they are different products with different registered uses in Singapore.

The weekly injection, up to 2.4 mg, is registered for chronic weight management. In the STEP 1 trial it produced average weight loss of about 15% over 68 weeks. (9)

The daily diabetes tablet, up to 14 mg, is registered for type 2 diabetes. Its effect on weight is smaller, and it needs the empty-stomach routine every morning.

Some people prefer a tablet to an injection; others prefer one dose a week with no daily rules. A doctor can help you decide which fits your health and your routine.

Fig. 4 — The semaglutide tablet versus the weekly semaglutide injection.
Fig. 4 — The semaglutide tablet versus the weekly injection.

Side effects and safety

Side effects are mostly gastrointestinal, mild to moderate, and most common in the first weeks and after each dose increase. Smaller meals and eating slowly often help. Seek medical advice quickly for severe, persistent stomach pain, which can be a sign of pancreatitis. (3)

Commonly reported effects

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Stomach pain
  • Reduced appetite
Book a Consultation & Check Your Eligibility
Weight loss can sometimes feel overwhelming and challenging. However, you do not have to face it alone. With the right treatment plan and professional guidance, you can achieve sustainable weight loss and reclaim your health with confidence.

Schedule a consultation with us today for a comprehensive body analysis and personalised treatment plan.
BOOK A CONSULTATION
Frequently asked questions
References

Studies and sources cited in this document

  1. U.S. Food and Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes. September 2019.
  2. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
  3. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Efficacy and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732.
  4. Wharton S, et al., for the OASIS 4 Investigators. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products: semaglutide. Checked November 2026.
  6. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402:705-719.
  7. McGuire DK, Marx N, Mulvagh SL, et al., for the SOUL Investigators. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025.
  8. Health Promotion Board, Singapore. Body Mass Index (BMI) cut-off points for Asian adults.
  9. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

Detect any underlying health conditions.

When was the last time you had your full medical check up? Take charge of your own health – Begin with a comprehensive full body medical check-up and speak to your doctor.

Please indicate your current problem or share any other remarks for us to note before your appointment.

Take charge of your health today.

Your submission has been received.
Your submission has been received. Our customer representative will contact you soon! For quicker response, please call us at +65 8129 8877
Oops! Something went wrong while submitting the form.